(b)(4).The product was not returned to abbott vascular for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no other incidents reported from this lot.In this case, the device was prepped prior to use without any leak or ruptures noted, which would suggest that the device was not damaged prior to use.It should be noted that the instructions for use (ifu), for the trek rx and mini trek rx, states: balloon pressure should not exceed the rated burst pressure (rbp).Use of a pressure-monitoring device is recommended to prevent over-pressurization.In this case, the reported ifu violation does not appear to have caused or contributed to the reported complaint.The investigation determined the reported difficulty to advance and balloon rupture appears to be related to operational circumstances of the procedure.In this case, based on the reported information, it is likely that during advancement and/or inflation, the balloon outer surface became compromised and/or damaged against the heavily calcified, mildly tortuous, 90% stenosed anatomy resulting in the balloon rupture.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that the procedure was performed to treat a de novo lesion in the heavily calcified, mildly tortuous, 90% stenosed right coronary artery.A 2x15mm mini trek balloon dilatation catheter (bdc) was advanced with resistance with the anatomy.During the first inflation, the balloon ruptured at 16 atmospheres.An unspecified balloon and stent were used to successfully complete the procedure.There were no adverse patient effects and no clinically significant delay in the procedure.No additional information was provided.
|